Roche's anti-TIGIT drug suffers a phase III cancer setback

被引：0
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [31] Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer.
    Hu, Yun
    Paris, Sebastien
    Barsoumian, Hampartsoum
    Sezen, Duygu
    He, Ke Wen
    Wasley, Mark
    Masrorpour, Fatemeh
    Yang, Peng Liang
    Puebla-Osorio, Nahum
    Cortez, Maria Angelica
    Welsh, James
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
  • [32] Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)
    Sarikonda, G.
    Wallace, B. K.
    Wiesner, C.
    Krishnan, S.
    Lewicki, J. A.
    Kapoun, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S589
  • [33] Anti-obesity drug - US FDA gives Roche's Xenical conditional OK
    不详
    EUROPEAN CHEMICAL NEWS, 1998, 69 (1813): : 27 - 27
  • [34] Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells (Feb, 10.1038/s41586-024-07121-9, 2024)
    Guan, Xiangnan
    Hu, Ruozhen
    Choi, Yoonha
    Srivats, Shyam
    Nabet, Barzin Y.
    Silva, John
    McGinnis, Lisa
    Hendricks, Robert
    Nutsch, Katherine
    Banta, Karl L.
    Duong, Ellen
    Dunkle, Alexis
    Chang, Patrick S.
    Han, Chia-Jung
    Mittman, Stephanie
    Molden, Nandini
    Daggumati, Pallavi
    Connolly, Wendy
    Johnson, Melissa
    Abreu, Delvys Rodriguez
    Cho, Byoung Chul
    Italiano, Antoine
    Gil-Bazo, Ignacio
    Felip, Enriqueta
    Mellman, Ira
    Mariathasan, Sanjeev
    Shames, David S.
    Meng, Raymond
    Chiang, Eugene Y.
    Johnston, Robert J.
    Patil, Namrata S.
    NATURE, 2024, 627 (8005) : E11 - E11
  • [35] Phase II study of anti-TIGIT GSK4428859A (GSK'859A)/EOS-448+anti-CD96 GSK6097608 (GSK'608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)
    Spigel, D. R.
    Garrido Lopez, P.
    Cousin, S.
    Cheema, P. K.
    Rodriguez, L. M.
    Garassino, M. C.
    Kijewska, M.
    Majumdar, A.
    Theti, D. S.
    Roy-Ghanta, S.
    Ballas, M.
    Reck, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1092 - S1092
  • [36] Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC.
    Drewett, Lynsey
    Pinilla, Karen A.
    Grybowicz, Louise
    Wulff, Jerome
    Dayimu, Alimu
    Demiris, Nikolaos
    Lucey, Rebecca
    Vallier, Anne-Laure
    Qian, Wendi
    Machin, Andrea
    McAdam, Karen
    Roylance, Rebecca
    Copson, Ellen R.
    Armstrong, Anne
    Levitt, Nicola
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    Abraham, Jean E.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Novel Alzheimer's drug enters Phase III trials
    不详
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2012, 16 (06) : 32 - 33
  • [38] Phase III trial of anti-tau drug generates mixed messages
    Heather Wood
    Nature Reviews Neurology, 2016, 12 (9) : 493 - 493
  • [39] Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Zhang, Jiayuan
    Tan, Wei
    Yan, Han
    Tian, Tian
    Zheng, Hao
    Zhou, Ziqi
    Wang, Ruihua
    Zhang, Yun
    Shen, Zhirong
    Kim, Hye Ryun
    Zhong, Diansheng
    Lu, Shun
    CANCER RESEARCH, 2024, 84 (07)
  • [40] AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas, Sophia
    Meniawy, Tarek
    Kao, Steven Chuan-Hao
    Wang, Ruihua
    Zuo, Yunxia
    Zheng, Hao
    Tan, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345